Innovative Immunotherapies: CAR-T Cell Therapy for Cancers: 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 23 January 2026 | Viewed by 576
Special Issue Editor
Interests: plasma cell disorders; multiple myeloma; amyloidosis; plasma cell leukemia; CAR-T
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Innovative immunotherapies, such as CAR-T, have shown advantageous outcomes in various cancer types. By modifying a patient's T cells, CAR-T targets specific antigens in cancer cells. This precision targeting allows for a particular attack on cancer cells while minimizing damage to healthy cells. However, it is important to note that CAR-T therapy has some difficulties and challenges; for example, it can be associated with significant side effects, including cytokine release syndrome and neurotoxicity. Improving CAR-T involves better target selection, higher potency, longer persistence, and overcoming resistance mechanisms that are employed by cancer cells to evade/escape the immune system. In this Special Issue, we will encourage novel approaches and perspectives of CAR-T cell therapy for cancers.
Dr. Shebli Atrash
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR-T
- NK-CAR
- immunotherapy
- cancer
- resistance mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
